Epidemiology

You have full text access to this OnlineOpen article

Risk of second malignant neoplasms among lymphoma patients with a family history of cancer

  1. Ola Landgren1,†,*,
  2. Ruth M. Pfeiffer1,
  3. Laveta Stewart1,
  4. Gloria Gridley1,
  5. Lene Mellemkjaer2,
  6. Kari Hemminki3,4,
  7. Lynn R. Goldin1,
  8. Lois B. Travis1

Article first published online: 27 NOV 2006

DOI: 10.1002/ijc.22414

Issue

International Journal of Cancer

International Journal of Cancer

Volume 120, Issue 5, pages 1099–1102, 1 March 2007

Additional Information

How to Cite

Landgren, O., Pfeiffer, R. M., Stewart, L., Gridley, G., Mellemkjaer, L., Hemminki, K., Goldin, L. R. and Travis, L. B. (2007), Risk of second malignant neoplasms among lymphoma patients with a family history of cancer. Int. J. Cancer, 120: 1099–1102. doi: 10.1002/ijc.22414

Author Information

  1. 1

    Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, MD

  2. 2

    Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen, Denmark

  3. 3

    Department of Biosciences at Novum, Karolinska Institute, Stockholm, Sweden

  4. 4

    Division of Molecular Genetic Epidemiology, German Cancer Research Center, Heidelberg, Germany

  1. †

    Fax: +301-402-4489.

*Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, 6120 Executive Boulevard, Bldg. EPS/Room 7110, Bethesda, MD 20892-7236, USA

Publication History

  1. Issue published online: 19 JAN 2007
  2. Article first published online: 27 NOV 2006
  3. Manuscript Accepted: 15 SEP 2006
  4. Manuscript Received: 15 MAY 2006

Funded by

  • NIH, National Cancer Institute, DCEG

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (73K)

References

  • 1
    Ries LAG, Harkins D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, Clegg L, Eisner MP, Horner MJ, Howlader N, Hayat M, Hankey BF, et al. SEER Cancer statistics review, 1975–2003. Bethesda, MD: National Cancer Institute, 2006.
  • 2
    van Leeuwen FE, Travis LB. Second cancers. In: DeVitaVTJ, HellmanS, RosenbergSA, eds. Cancer: principles and practice of oncology, 7th edn. Philadelphia: Lippincott, 2005. 2575–602.
  • 3
    Hoppe RT. Hodgkin's disease: complications of therapy and excess mortality. Ann Oncol 1997; 8 ( Suppl 1): 115–18.
  • 4
    Aleman BM, van den Belt-Dusebout AW, Klokman WJ, Van't Veer MB, Bartelink H, van Leeuwen FE. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol 2003; 21: 3431–9.
  • 5
    Travis LB, Hill D, Dores GM, Gospodarowicz M, van Leeuwen FE, Holowaty E, Glimelius B, Andersson M, Pukkala E, Lynch CF, Pee D, Smith SA, et al. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst 2005; 97: 1428–37.
  • 6
    Travis LB, Hill DA, Dores GM, Gospodarowicz M, van Leeuwen FE, Holowaty E, Glimelius B, Andersson M, Wiklund T, Lynch CF, Van't Veer MB, Glimelius I, et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA 2003; 290: 465–75.
  • 7
    van Leeuwen FE, Klokman WJ, Stovall M, Dahler EC, van't Veer MB, Noordijk EM, Crommelin MA, Aleman BM, Broeks A, Gospodarowicz M, Travis LB, Russell NS. Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst 2003; 95: 971–80.
  • 8
    Hill DA, Gilbert E, Dores GM, Gospodarowicz M, van Leeuwen FE, Holowaty E, Glimelius B, Andersson M, Wiklund T, Lynch CF, Van't Veer M, Storm, H et al. Breast cancer risk following radiotherapy for Hodgkin lymphoma: modification by other risk factors. Blood 2005; 106: 3358–65.
  • 9
    Nichols KE, Levitz S, Shannon KE, Wahrer DC, Bell DW, Chang G, Hegde S, Neuberg D, Shafman T, Tarbell NJ, Mauch P, Ishioka C, et al. Heterozygous germline ATM mutations do not contribute to radiation-associated malignancies after Hodgkin's disease. J Clin Oncol 1999; 17: 1259.
  • 10
    Hemminki K, Vaittinen P. National database of familial cancer in Sweden. Genet Epidemiol 1998; 15: 225–36.
    Direct Link:
  • 11
    Hemminki K, Li X, Plna K, Granstrom C, Vaittinen P. The nation-wide Swedish family-cancer database–updated structure and familial rates. Acta Oncol 2001; 40: 772–7.
  • 12
    Goldin LR, Pfeiffer RM, Gridley G, Gail MH, Li X, Mellemkjaer L, Olsen JH, Hemminki K, Linet MS. Familial aggregation of Hodgkin lymphoma and related tumors. Cancer 2004; 100: 1902–8.
    Direct Link:
  • 13
    Landgren O, Linet MS, McMaster ML, Gridley G, Hemminki K, Goldin LR. Familial characteristics of autoimmune and hematologic disorders in 8,406 multiple myeloma patients: a population-based case-control study. Int J Cancer 2006; 118: 3095–98.
    Direct Link:
  • 14
    Landgren O, Engels EA, Caporaso NE, Gridley G, Mellemkjaer L, Hemminki K, Linet MS, Goldin LR. Patterns of autoimmunity and subsequent chronic lymphocytic leukemia in Nordic countries. Blood 2006; 108: 292–6.
  • 15
    Travis LB, van Leeuwen FE. Second Cancers. In: MauchPM, ArmitageJO, HarrisNL, Dalla-FaveraR, CoiffierB, eds. Non-Hodgkin's lymphomas. Philadelphia: Lippincott Williams and Wilkins, 2004; 539–48.
  • 16
    Hisada M, Biggar RJ, Greene MH, Fraumeni JF,Jr, Travis LB. Solid tumors after chronic lymphocytic leukemia. Blood 2001; 98: 1979–81.
  • 17
    Dores GM, Metayer C, Curtis RE, Lynch CF, Clarke EA, Glimelius B, Storm H, Pukkala E, van Leeuwen FE, Holowaty EJ, Andersson M, Wiklund T, et al. Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. J Clin Oncol 2002; 20: 3484–94.
  • 18
    Cox DR. Regression models and life tables (with discussion). J R Stat Soc B 1972; 34: 187–220.
  • 19
    Honrado E, Osorio A, Palacios J, Milne RL, Sanchez L, Diez O, Cazorla A, Syrjakoski K, Huntsman D, Heikkila P, Lerma E, Kallioniemi A, et al. Immunohistochemical expression of DNA repair proteins in familial breast cancer differentiate BRCA2-associated tumors. J Clin Oncol 2005; 23: 7503–11.
  • 20
    Travis LB, Gospodarowicz M, Curtis RE, Clarke EA, Andersson M, Glimelius B, Joensuu T, Lynch CF, van Leeuwen FE, Holowaty E, Storm H, Glimelius I, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst 2002; 94: 182–92.
  • 21
    Mudie NY, Swerdlow AJ, Higgins CD, Smith P, Qiao Z, Hancock BW, Hoskin PJ, Linch DC. Risk of second malignancy after non-Hodgkin's lymphoma: a British Cohort Study. J Clin Oncol 2006; 24: 1568–74.
  • 22
    van Leeuwen FE, Klokman WJ, Stovall M, Hagenbeek A, van den Belt-Dusebout AW, Noyon R, Boice JD,Jr, Burgers JM, Somers R. Roles of radiotherapy and smoking in lung cancer following Hodgkin's disease. J Natl Cancer Inst 1995; 87: 1530–7.
  • 23
    Gilbert ES, Stovall M, Gospodarowicz M, Van Leeuwen FE, Andersson M, Glimelius B, Joensuu T, Lynch CF, Curtis RE, Holowaty E, Storm H, Pukkala E, et al. Lung cancer after treatment for Hodgkin's disease: focus on radiation effects. Radiat Res 2003; 159: 161–73.
  • 24
    Blot WJ, Fraumeni JF,Jr. Cancers of the lung and pleura. In: SchottenfeldD, FraumeniJF,Jr, eds. Cancer epidemiology and prevention, 2nd edn. New York: Oxford University Press, 1996. 637–65.
  • 25
    Stagnaro E, Tumino R, Parodi S, Crosignani P, Fontana A, Masala G, Miligi L, Nanni O, Ramazzotti V, Rodella S, Senoiri Constantini A, Vigano C, et al. Non-Hodgkin's lymphoma and type of tobacco smoke. Cancer Epidemiol Biomarkers Prev 2004; 13: 431–7.
  • 26
    Morton LM, Holford TR, Leaderer B, Boyle P, Zahm SH, Zhang Y, Flynn S, Tallini G, Zhang B, Owens PH, Zheng T. Cigarette smoking and risk of non-Hodgkin lymphoma subtypes among women. Br J Cancer 2003; 89: 2087–92.
  • 27
    Nugent Z, Demers AA, Wiseman MC, Mihalcioiu C, Kliewer EV. Risk of second primary cancer and death following a diagnosis of nonmelanoma skin cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 2584–90.
  • 28
    Travis LB, Curtis RE, Hankey BF, Fraumeni JF,Jr. Second cancers in patients with chronic lymphocytic leukemia. J Natl Cancer Inst 1992; 84: 1422–7.
  • 29
    Travis LB, Curtis RE, Glimelius B, Holowaty EJ, Van Leeuwen FE, Lynch CF, Hagenbeek A, Stovall M, Banks PM, Adami J, et al. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. J Natl Cancer Inst 1995; 87: 524–30.
  • 30
    Morrison VA, Rai KR, Peterson BL, Kolitz JE, Elias L, Appelbaum FR, Hines JD, Shepherd L, Larson RA, Schiffer CA. Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011. J Clin Oncol 2002; 20: 3878–84.
  • 31
    Cheson BD, Vena DA, Barrett J, Freidlin B. Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias. J Clin Oncol 1999; 17: 2454–60.
  • 32
    World Health Organisation. Monographs on the evaluation of carcinogenic risks to humans–overall evaluation of carcinogenety, vol. 42. Lyon: IARC, 1987.
  • 33
    Shamash J, Dancey G, Barlow C, Wilson P, Ansell W, Oliver RT. Chlorambucil and lomustine (CL56) in absolute hormone refractory prostate cancer: re-induction of endocrine sensitivity an unexpected finding. Br J Cancer 2005; 92: 36–40.
  • 34
    Goldin LR, Pfeiffer RM, Li X, Hemminki K. Familial risk of lymphoproliferative tumors in families of patients with chronic lymphocytic leukemia: results from the Swedish Family-Cancer Database. Blood 2004; 104: 1850–4.
  • 35
    Travis LB, Rabkin CS, Brown LM, Allan JM, Alter BP, Ambrosone CB, Begg CB, Caporaso N, Chanock S, DeMichele A, Figg WD, Gospodarowicz MK et al. Cancer survivorship–genetic susceptibility and second primary cancers: research strategies and recommendations. J Natl Cancer Inst 2006; 98: 15–25.
View Full Article (HTML) Get PDF (73K)